Shares of Immunomedics (IMMU) are in the spotlight on Wednesday after the company announced that the Food and Drug Administration approved Trodelvy for the treatment of adult patients with metastatic triple-negative breast cancer, or TNBC, who have received at least two prior therapies for metastatic disease. Commenting on the… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3077182/-Immunomedics-in-spotlight-following-accelerated-approval-for-breast-cancer-drug)